Top

International Journal of Clinical Oncology

Published in:

01-08-2012 | Original Article

Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients

Authors: Yuichiro Hiura, Shuji Takiguchi, Kazuyoshi Yamamoto, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Hiroshi Miyata, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro Doki

Published in: International Journal of Clinical Oncology | Issue 4/2012

Abstract

Background

Chemotherapeutic agents, especially cisplatin, cause severe gastrointestinal disorders, including nausea, vomiting, and anorexia, which markedly impair quality of life and encourage discontinuation of chemotherapy. Since cisplatin was recently reported to decrease plasma ghrelin and food intake in rodents, we monitored the plasma ghrelin level and its association with nutritional status and adverse events during chemotherapy in patients with esophageal cancer.

Patients and methods

Twenty patients with advanced esophageal cancer who underwent cisplatin-based neoadjuvant chemotherapy were enrolled in a prospective observational study. Changes in gastrointestinal hormones including ghrelin were measured and correlated with feeding activity, including appetite and dietary intake, nutritional status including rapid turnover proteins, and adverse events from chemotherapy.

Results

Plasma total ghrelin significantly decreased at days 3 and 8 of chemotherapy but recovered at day 28 (baseline: 140 ± 54; day 3: 107 ± 46; day 8: 82 ± 32; day 28: 126 ± 43 fmol/ml; p = 0.023 for day 3 and p = 0.034 for day 8). No changes were noted in plasma leptin (baseline: 3.2 ± 1.8; day 8: 2.5 ± 1.5 ng/ml; p = 0.18). Among blood nutritional parameters, transferrin was the only parameter that decreased significantly and its decline, as well as loss of oral intake and appetite, correlated significantly with plasma ghrelin levels (p = 0.0013, p = 0.0063, and p = 0.013, respectively). Neutropenia and anorexia were more frequent in patients with low plasma ghrelin than in those with high plasma ghrelin (p = 0.015 and p = 0.011, respectively).

Conclusion

Cisplatin-based chemotherapy significantly reduced plasma ghrelin and feeding activity. Ghrelin is a potentially useful novel therapy for minimizing the adverse effects of chemotherapy.

Kranzfelder M, Buchler P, Lange K et al (2010) Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature. J Am Coll Surg 210:351–359PubMedCrossRef

Bedenne L, Michel P, Bouche’ O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168PubMedCrossRef

Ajani JA, Barthel JS, Bekaii-Saab T et al (2008) Esophageal cancer. J Natl Compr Canc Netw 6:818–849PubMed

Akita H, Doki Y, Yano M et al (2009) Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus 22:291–297PubMedCrossRef

Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with and without chemotherapy in oesophageal cancer. Lancet 359:1727–1733

Yano M, Takachi K, Doki Y et al (2006) Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 19:158–163PubMedCrossRef

Matsuyama J, Doki Y, Yasuda T et al (2007) The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141:570–580PubMedCrossRef

Hesketh PJ, Van Belle S, Aapro M et al (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074–1080PubMedCrossRef

Cubeddu LX, Hoffmann IS (1993) Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 33:691–697PubMed

10.

Butcher ME (1993) Global experience with ondansetron and future potential. Oncology 50:191–197PubMedCrossRef

11.

Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef

12.

Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198PubMedCrossRef

13.

Van der Lely AJ, Tschop M, Heiman ML et al (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426–457PubMedCrossRef

14.

Korbonits M, Goldstone AP, Gueorguiev M et al (2004) Ghrelin—a hormone with multiple functions. Front Neuroendocrinol 25:27–68PubMedCrossRef

15.

Akamizu T, Kangawa K (2006) Translation research on the clinical applications of ghrelin. Endocr J 53:585–591PubMedCrossRef

16.

Ariyasu H, Iwakura H, Yamada G et al (2008) Efficacy of ghrelin as a therapeutic approach for age related physiological changes. Endocrinology 149:3722–3728PubMedCrossRef

17.

Shintani M, Ogawa Y, Ebihara K et al (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232PubMedCrossRef

18.

Adachi S, Takiguchi S, Okada K et al (2010) Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 138:1312–1320PubMedCrossRef

19.

Yamamoto K, Takiguchi S, Miyata H et al (2010) Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery 141:31–38CrossRef

20.

Liu Y-L, Malik NM, Sanger GJ et al (2006) Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 58:326–333PubMedCrossRef

21.

Takeda H, Sadakane C, Hattori T et al (2008) Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 134:2004–2013PubMedCrossRef

22.

Shimakawa T, Naritaka Y, Asaka S et al (2008) Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer. Anticancer Res 28:2321–2326PubMed

23.

Tanaka Y, Yoshida K, Sanada Y et al (2010) Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol 66:1159–1165PubMedCrossRef

24.

Takahashi H, Arimura Y, Yamashita K et al (2010) Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 1:122–128CrossRef

25.

CTCAE v4.0. https://cabig-kc.nci.nih.gov/Vocab/KC/index.php/CTCAE

26.

Japanese Society for Esophageal Diseases (2001) Guidelines for clinical and pathologic studies on carcinoma in the esophagus, 9th edn. Kanehara & Co., Ltd, Tokyo

27.

Akamizu T, Shinomiya T, Irako T et al (2005) Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab 90:6–9PubMedCrossRef

28.

Nonogaki K, Nozue K, Oka Y (2006) Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in A^y mice. Endocrinology 147:5893–5900PubMedCrossRef

29.

Castejon AM, Paez X, Hernandez L et al (1999) Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 291:960–966PubMed

30.

Cubeddu LX, Hoffmann IS, Fuenmayor NT et al (1992) Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 66:198–203PubMedCrossRef

31.

Barnes NM, Ge J, Jones WG et al (1990) Cisplatin-induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine. Br J Cancer 62:862–864PubMedCrossRef

32.

Du Bois A, Vach W, Siebert C et al (1997) The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens. Support Care Cancer 5:212–218PubMedCrossRef

33.

Wilder-Smith OHG, Borgeat A, Chappuis P et al (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72:2239–2241PubMedCrossRef

34.

Latreille J, Pater J, Johnston D et al (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174–1178PubMed

35.

Olver I, Paska W, Depierre A et al (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945–952CrossRef

36.

Cocquyt V, Van Belle S, Reinhardt RR et al (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835–842PubMedCrossRef

37.

Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:535–546CrossRef

38.

Gerald MH, Miklos LA, Ramin A et al (2006) 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Practice 12:201–209CrossRef

39.

Campos D, Pereira JR, Reinhardt RR et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767PubMed

40.

Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high dose cisplatin—The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119PubMedCrossRef

41.

Herrstedt J, Muss HB, Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548–1555PubMedCrossRef

42.

Takahashi T, Hoshi E, Takagi M et al (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 101:2455–2461PubMedCrossRef

43.

Arrieta O, Michel Ortega RM et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10:50PubMedCrossRef

44.

Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe hematological toxicity following chemotherapy. Ann Oncol 14:36–41PubMedCrossRef

45.

Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed

46.

Andreyev HJ, Norman AR, Oates J et al (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503–509PubMedCrossRef

47.

Blay JY, Chauvin F, Le Cesne A et al (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636–643PubMed

48.

Kalra SP, Kalra PS (2003) Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine 22:49–56PubMedCrossRef

Title: Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients
Authors: Yuichiro Hiura
Shuji Takiguchi
Kazuyoshi Yamamoto
Yukinori Kurokawa
Makoto Yamasaki
Kiyokazu Nakajima
Hiroshi Miyata
Yoshiyuki Fujiwara
Masaki Mori
Yuichiro Doki
Publication date: 01-08-2012
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0289-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel–carboplatin and docetaxel–carboplatin therapy

Dominant lymph drainage in the facial region: evaluation of lymph nodes of facial melanoma patients

Current status of interventional oncology

Primary retroperitoneal mucinous cystadenocarcinoma with mural nodules: a case report and literature review

Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations

A case of myxofibrosarcoma of the maxilla with difficulty in preoperative diagnosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer